Breast Cancer
Conditions
Keywords
breast cancer,, tamoxifen,, ER/PR negative, ER-beta positive
Brief summary
The current study is a multicentre, randomized,double-blind, prospective clinical trial stratified patients by the HER2 status of their cancer (negative or positive) which is sponsored by the researchers. The trial is designed to evaluate the effectiveness of tamoxifen as adjuvant therapy for ER(ER-α)/PR negative, ER-β positive operable breast cancer patients. 688 female ER(ER-α)/PR negative, ER-β(wild type ER-β1) positive operable breast cancer patients who had undergone neoadjuvant chemotherapy or directly modified radical mastectomy or breast-conserving surgery were randomly (1:1) enrolled to receive tamoxifen (20 mg per day) or placebo (2# per day) within 6 weeks after postoperative chemotherapy and/or radiation therapy if needed (according to 2013 NCCN breast cancer guideline). If the breast tumor's HER2 is positive, the patient can receive targeted therapy (Herceptin) combined with tamoxifen or placebo. The follow-up time will be eight years. The aim of this trial is to evaluate the effectiveness of tamoxifen as adjuvant therapy for ER(ER-α)/PR negative, ER-β positive operable breast cancer patients by comparing the DFS and OS between tamoxifen group and placebo group and to determine whether the percentage of positive ER-β expression is associated with the response to the hormone therapy in breast cancer.
Interventions
DRUGTamoxifen
20 mg(2#)/day, PO, daily
DRUGPlacebo
2#/day, PO, daily
Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* The patients signed the written informed consent * The patients present with operable unilateral invasive breast cancers without distant metastasis(stage I, II, and III) * The breast tumor's positive ER/PR rate is \<1%, and positive ER-beta1 rate is ≥10% by IHC. * The patients have no history of neoadjuvant hormone therapy. * The patients have normal cardiac functions by echocardiography. * The patients' ECOG scores are ≤0-2. * Female patient who is ≥ 18yrs, and ≤ 70yrs. * The patients are non-pregnant, and disposed to practice contraception during the whole trial. * The patients underwent neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection) after diagnosis of breast cancer. * The patients underwent chemotherapy, radiation therapy or targeted therapy(herceptin) after surgery according to the 2013 NCCN guideline. * The results of patients' blood tests are as follows: Hb≥90g/L; WBC≥4.0×109/L; Plt≥100×109/L; Neutrophils≥1.5×109/L; ALT and AST ≤ triple of normal upper limit; TBIL ≤ 1.5 times of normal upper limit; Creatinine ≤ 1.25 times of normal upper limit.
Exclusion criteria
* The patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus; * The patients have active infections that were not suitable for chemotherapy; * The patients have severe non-cancerous diseases. * The patients have history of neoadjuvant hormone therapy. * The patients have bilateral breast cancers or DCIS or metastatic breast cancers. * The patients are undergoing current administration of anti-cancer therapies, or are attending other clinical trials. * The patients are pregnant or lactational, or they refuse to practice contraception during the whole trial. * The patients are in some special conditions that they can't understand the written informed consent, such as they are demented or hawkish. * The patients have allergic history or contraindication of tamoxifen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival of patients | within 10 years after diagnosis |
Secondary
| Measure | Time frame |
|---|---|
| Rates of adverse reactions | within 5 years when patients is undergoing tamoxifen or placebo treatment |
| Distant metastasis-free survival | within 10 years after diagnosis |
| Overall survival | within 10 years after diagnosis |
Countries
China
Contacts
Primary ContactErwei Song, M.D., Ph. D.
Backup ContactQiang Liu, M.D., Ph. D.
Outcome results
None listed